Moreover, we established stringent participant selection criteria, that specifically excluded pregnant individuals, those undergoing sex hormone therapy, and those with missing information on SHBG levels and MetS, thereby bolstering the study’s reliability. This evidence concerns the gene SHBG and metabolic syndrome.